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Evidence has accumulated since 1967 indicating the importance of the immune
system in malignant melanoma. Morton et al.'s initial work described tumor-
associated antigens in human malignant melanoma using immunofluorescent tech-
niques (1). These were soon confirmed and extended by others.
Further work showed that these tumor-specific antigens elicit the production of
circulating humoral antibodies in 60% ofpatients with malignant melanoma (Table
1). Only 20% of normal patients had these antibodies, which may have been the re-
sult of their surveillance mechanism identifying and destroying these tumors. Sur-
veillance is the mechanism by which the host immune system, either by the T-cell
lymphocytes or by circulating antibodies, seeks out anddestroys what itidentifies as
foreign to the host. Furthermore, there appeared to be a correlation between the
clinical status of the melanoma patients and the incidence of anti-melanoma anti-
bodies in their sera. Patients with localized melanoma were more likely to have anti-
body in their sera than those patients with disseminated disease (2). Some patients
who were observed through their course had the antibody disappear from their sera
as the disease progressed. Transfusions from patients with spontaneous regression
have been reported to cause regression ofmalignant melanoma in certain cases.
To understand immunotherapy, we must first explain that the immune response
can be separated into an antibody and a cellular response (Fig. 1). The antibody
response can be seen to result in opposing forms: the emergence of cytotoxic anti-
bodies can be shown to kill tumor cells when incubated in vitro with complement,
whereas enhancing "antibody," or "blocking factor," is believed to be a complex
formed by the binding of fragments of tumor antigen to circulating tumor-specific
antibodies (3). This blocking ofthe immune mechanism is thought to be directed at
the host's lymphoid cells by masking its recognition of tumor or preventing its
cytotoxic effects against the tumor. It can be seen that both responses may react in-
versely with the removal oftumor.
On the other hand, tumors may also elicit a cellular response through the
lymphocytes and macrophages (Fig. 1). The lymphocytes can become immunized
and demonstrate their killing potential when cultured in vitro with the tumor cells.
This mechanism, called cytotoxicity, is employed to test the immunologic
competence of the individual. Macrophages can also become immunized to release
their toxic contents to kill tumor cells. There may also be an interaction between im-
munized lymphocytes and macrophages to potentiate this effect, as shown by in vivo
studies in animals.
However, these immunologic responses to tumor are in dynamic motion and are
changing constantly. This can be exemplified by folding and superimposing these
two circles (Fig. 2). One must appreciate the fact that the immune response ofany
individual to the tumor is a multiplicity of actions that make up the whole immu-
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TABLE 1
Human Anti-Melanoma Antibodya
27 patients with MM-61% had anti-MM Ab
25 normal patients-20% had anti-MM Ab
Transfusion of blood from spontaneous regression induced regression of MM
aFrom Ref. (1).
nologic response. There is adelicate balance, the end result ofwhich is a reflection of
whatever mechanisms become more dominant in the individual, to cause either
growth or death ofthe tumor.
There is evidence to suggest that the manipulation ofthe immune system may fa-
vorably affect the clinical course of patients (Fig. 3). The immune response may be
specifically augmented by passive transfer ofleukocytes from patients recovered or
cured of a melanoma (4, 5). Another way would be to pass "transfer factor" from
immune patients (6). A similar response may follow the use of anti-HL-A serum,
which seems to increase the survival time of immune lymphoid cells. Active im-
munity, on the other hand, may be potentiated by altering or increasing the anti-
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FIG. 2. Superimposition ofthe antibody and cellular responses ofthe immune reaction.
genicity of tumor by a number of reactions to remove the "coating" of the tumor
cells, such as acetylation (7), concanavalin A (8), and neuraminidase (9, 10).
Nonspecific augmentation utilizes agents to increase the response ofthe lymphoid
cells, in general, to react and kill tumor cells. DNCB has been applied topically to
squamous cell carcinoma ofthe skin to cause a delayed hypersensitivity reaction and
thereby destroy adjacent tumor cells as well (11). This mechanism may also employ
the formation of hapten conjugates. Other agents may be used to increase the im-
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FIG. 3. Techniques ofimmune system manipulation.
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TABLE 2
Regression by Attenuated Virus Vaccinea
1960-1965, 30 cases
Smallpox vaccine injected directly into lesions
Most had some regression of tumor
Four cases had significant prolongation of life
All patients had severe systemic and local reactions to virus
aFrom Ref. (12).
mune response nonspecifically, such as smallpox and BCG vaccines. BCG may also
be used to increase systemic immunity.
The use of smallpox vaccine injected directly into melanoma skin nodules was
shown in a small series to result in regression ofsatellite nodules and to prolong sur-
vival in a few cases (Table 2) (12). All had severe systemic reactions to the virus.
However, no response could be demonstrated with repeated injections in patients
who had been immunized to the vaccine recently or in visceral metastases. Again,
this reflected a nonspecific response to activation oftheimmune mechanism.
The use of BCG to stimulate the immune response was reported by Morton et al.
in 1970 in a small series of eight patients treated by direct intralesional injections
with the vaccine (13). Approximately 90% of the melanotic nodules regressed in
those patients who were immunologically competent (as measured by delayed
hypersensitivity reactions to DNCB) (Table 3). Moreover, occasional nodules at
sites distant from the BCG inoculations also regressed in some patients. In fact, one
patient remained completely free oftumor for 2 yr.
The potential dangers of this type oftherapy, however, must be emphasized. The
intralesional injections of BCG frequently result in fevers ofup to 103-105° F, chills,
abscesses in the local areas ofinjections, and sinuses that have drained for months
(14). Regional lymphadenitis has been frequent, and occasionally a systemic in-
fection has occurred with associated granulomatous hepatitis. Although not ob-
served in Morton et al.'s series, fatal anaphylactoid reactions have been reported
(but unpublished) following repeated administrations oflargedoses ofBCG vaccine.
In contrast, the multiple intradermal scarification technique has been tolerated
well with only mild fever and malaise for short periods following vaccination (14).
When the two modes of administration of the vaccine were compared among
patients in Uganda, where there is a high incidence of melanoma, the remission
following surgical removal and vaccination was longer among those that were
treated by scarification than by intradermal injections (15). This technique has been
presently modified to the multiple intradermal punctures of the Tine technique, as
employed with tuberculin tests.
The largest series ofimmunotherapy in malignant melanoma comes from UCLA,
where Morton et al. recently reported their results in 151 patients over the past 7 yr
(14). In an uncontrolled series, patients with Clinical Stage III melanoma treated
TABLE 3
BCG Regression ofMelanomase
8 patients-DNCB-5 positive, 3 negative
3 negative-no regression of 219 nodules
5 positive-90% of 184 nodules complete regression, 1 patient
completely free for 2.5 yr
aFrom Ref. (13).
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FIG. 4. Experimental model for tumor growth on vascular island pedicle deprived of lymphatic
drainage.
with BCG immunization may have a lower recurrence rate and longer survival rate
than those treated elsewhere without BCG immunization. In Stage II melanoma,
moreover, where immunotherapy with BCG was begun 3-6 weeks following the sur-
gical removal ofthe disease, the overall tumor-free rate for this group of67 patients
treated with BCG immunization is higher at all points in time when compared to 34
patients seen at UCLA during the same interval who did not receive BCG im-
munotherapy.
Nevertheless, patients with subcutaneous or visceral metastases did not respond
as well (30%) as those with intradermal metastases (91%) (14). Rarely was thereevi-
dence of regression of uninjected or grossly visible visceral metastases in these
patients. In general, patients with large, bulky lesions or visceral metastases did not
benefit significantly from the BCGimmunotherapy alone.
The explanation for the differences in response between these two types of
patients is not completely clear at the present time. There are several possibilities,
however, that deserve consideration.
First, there may be some biological difference between the behavior of melanoma
metastatic to skin and to visceral organs. However, this may be more quantitative
than qualitative and may reflect a later stage of the disease, because patients who
present with intracutaneous metastatic disease almost invariably develop visceral
metastases within thefirst year and eventually die oftheir disease.
This is compatible with the second observation, that the lack of im-
munocompetence is a manifestation of the tumor burden. The patients who are
most frequently anergic asjudged by the hypersensitivity parameters are those who
have visceral and subcutaneous metastatic lesions. Therefore, it is not surprising
that these patients would not respond well to the intradermal injections ofBCG.
Finally, and more probably, the skin nodules may respond to thevaccine more in-
tensely because the skin is the site ofthe most intense hypersensitivity reaction. The
best way to immunize an animal is to incorporate an antigen in an inflammatory
focus, usually into the skin, and invariably in skin where it is drained by regional
nodes. It may have something to do with the rich lymphatic supply ofthe skin. It has
been shown experimentally that tumor growth is potentiated in animals ifthe tumor
is grown on a vascular island pedicle of skin that has been elevated and deprived of
its lymphatic drainage (16). This is called a "privileged site" (Fig. 4).
As to the mechanism of tumor regression, it is possible that the melanoma cells
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are destroyed by the immunologic reaction against the BCG-associated antigens as
a result of an intense inflammatory reaction by lymphocytes and macrophages. In-
tradermal lesions have been shown to be infiltrated by macrophages, causing the
death oftumor cells after BCG injection without phagocytosis ofthe tumor cells (5).
Electron microphotographs have shown BCG-immune macrophage cleaving the
membrane of the tumor cell, causing its degeneration as indicated by its dark ap-
pearance, but again no phagocytosis ofthe tumor cell was seen (17).
We have investigated the role of BCG in our laboratory to determine the
mechanism of tumor cell death. The injection of two similar but antigenically dis-
tinct tumor types into an animal immune to only one of the tumors resulted in
significant necrosis of nearby macrophages leading to the death of adjacent tumor
cells of both types (18). However, the cells were not killed if the macrophages had
not been previously immunized or "activated." The suppression of the growth of
tumor cells was demonstrated only when macrophages activated by BCG immuni-
zatiort were added to the inocula of tumor-immune lymphocytes and tumor cells
into normal animals (19). Merely adding BCG to the inocula did not suppress the
growth oftumor cells.
Macrophages are rich in lysozymes, and it is suggested that the BCG immuniza-
tion increases the potential of the macrophages to kill the tumor cells, which it may
do by two possible routes (Fig. 5). It may "activate" the macrophages to kill the
tumor with or without the presence of tumor-immune lymphocytes; in the latter
®) BCG i (i)
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FIG. 5. Activation of macrophages by BCG, which then become cytotoxic in the presence of tumor-
immune lymphocytes and tumor antigens.
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case we shall say the role oftheimmune lymphocyte may be merely to recognize the
tumor and "fire" the activated macrophage to release its toxic enzymes. Al-
ternately, BCG may "arm" the macrophages, which are not cytotoxic as yet, but re-
quire the presence of tumor antigen and tumor-immune lymphocytes to be made
cytotoxic against tumor cells (18, 19). In either event, the macrophages are caused
to release their cytotoxic enzymes killing adjacent tumor cells.
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